Non-surgical gum treatment effects on saliva markers in smokers and non-smokers with periodontitis
The Significance of Non-Surgical Periodontal Therapy on Salivary Dkk-1, Sclerostin, and PLAP-1 Levels in Smoker and Non-Smoker Patients With Periodontitis: A Clinical Comparative Study
This test will see if deep cleaning (scaling and root planing) changes saliva markers linked to bone loss in adults with Stage II–III periodontitis, comparing current smokers and non-smokers.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 44 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Al-Mustansiriyah University Academic / other |
| Locations | 2 sites (Baghdad, Baghdad Governorate and 1 other locations) |
| Trial ID | NCT07547202 on ClinicalTrials.gov |
What this trial studies
This non-randomized comparative study enrolls 44 systemically healthy adults with Stage II or III periodontitis, split into 22 current smokers and 22 non-smokers. Participants provide unstimulated whole saliva and undergo a full-mouth clinical exam at baseline, receive standardized non-surgical periodontal therapy (scaling and root planing), and return for repeat saliva collection and clinical measurements six weeks later. The study measures salivary levels of Dkk-1, sclerostin (SOST), and PLAP-1 alongside standard periodontal clinical parameters to track biological and clinical changes. The goal is to compare biomarker and clinical responses to therapy between smokers and non-smokers.
Who should consider this trial
Good fit: Systemically healthy adults with Stage II or III periodontitis who have at least 20 teeth and are either current smokers or non-smokers (never smoked or quit >5 years ago) are the intended participants.
Not a fit: Patients with systemic diseases affecting the periodontium, recent antibiotic use or periodontal therapy, current alcohol use, or fewer than 20 teeth would be excluded and are unlikely to benefit from this specific protocol.
Why it matters
Potential benefit: If successful, saliva markers could be used to monitor treatment response and help tailor periodontal care, particularly for people who smoke.
How similar studies have performed: Non-surgical periodontal therapy is known to improve clinical measures and prior work links Dkk-1 and sclerostin to periodontal bone loss, but how these salivary biomarkers collectively respond to therapy in smokers is not well characterized.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Systemically healthy. * Diagnosed with Stage II and III periodontitis. * Presence of ≥ 20 teeth (excluding third molars). * Current smoker OR non-smoker Exclusion Criteria: * Presence of systemic diseases affecting the periodontium. * Use of medications affecting inflammation. * Received periodontal therapy in the past 6 months. * Received antibiotic therapy in the last 3 months. * Alcohol use.
Where this trial is running
Baghdad, Baghdad Governorate and 1 other locations
- Al-Sadr Specialized Dental Center — Baghdad, Baghdad Governorate, Iraq (Recruiting)
- Sadr Specialized Dental Center — Baghdad, Baghdad Governorate, Iraq (Recruiting)
Study contacts
- Principal investigator: Hussein Abdul-Rassul Hatiem, B.D.S., M.Sc. Student — College of Dentistry / Mustansiriyah University
- Study coordinator: Hussein Abdul-Rassul Hatiem, B.D.S., M.Sc. Student
- Email: husseinabdulrassol@uomustansiriyah.edu.iq
- Phone: +9647703916382
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.